KP-2326

KP-2326 is a **preclinical analogue of etelcalcetide**, a peptide **calcimimetic** designed for experimental study of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD)[1][2][3][5][7]. KP-2326 acts as an allosteric activator of the calcium-sensing receptor, leading to reduced parathyroid hormone (PTH) secretion[5]. Studies have investigated its effects in animal models of CKD, showing that KP-2326 mitigates progression of cortical bone porosity, inhibits osteoclast differentiation and bone resorption, and improves bone material properties through increased mineral crystallinity and reduced carbonate substitution[1][2][7]. Unlike vitamin D analogues, KP-2326 maintains efficacy in advanced CKD where resistance to vitamin D is common[2][4]. Its mechanism supports the management of CKD-related mineral and bone disorder (CKD-MBD) and has shown benefits on bone quality and mechanical properties in preclinical studies[1][7].

Other names

KP2326KP-2326KP 2326